Guangdong Hec Pharmaceutical Co., Ltd. and Hong Kong Hec Sales Co., Ltd completed the acquisition of 51.4% stake in Yichang Dongyangguang Pharmaceutical Co., Ltd. from Guangdong Hec Technologyholding Co., Ltd.
December 30, 2021
Share
Guangdong Hec Pharmaceutical Co., Ltd. and Hong Kong Hec Sales Co., Ltd. intends to acquire 51.4% stake in Yichang Dongyangguang Pharmaceutical Co., Ltd. from Guangdong Hec Technologyholding Co., Ltd (SHSE:600673) on September 1, 2021. As per the transaction, Guangdong Hec Technologyholding Co., Ltd will sell 4.524 billion shares which consists of 2.262 billion domestic shares and 2.262 billion H-share "fully-tradable" shares. The consideration is paid in cash, among which the consideration for the domestic shares of the target company shall be paid in CNY, and the consideration for the H-share "fully circulating" shares of the target company shall be paid in HKD. As of November 11, 2021, the transaction was approved by the board of directors of Guangdong Hec Technologyholding Co., Ltd. and shareholders of acquirer. This transaction and related matters involved in this transaction still need to be reviewed and approved by the shareholders' meeting of Guangdong Hec Technologyholding Co., Ltd. As of June 30, 2021, Yichang Dongyangguang Pharmaceutical Co., Ltd. has reported total assets of CNY 8.9 billion and net assets of CNY 4.59 billion. The transaction will be approved by the Board of Directors of Guangdong Hec Technologyholding Co., Ltd. As of December 21, 2021, transaction is approved by the shareholders of Guangdong Hec Technologyholding Co., Ltd.
Jiang Yu of Huatai United Securities acted as financial advisor and Yan Yu, Wen Liangjuan and Wu Junchao of Jiayuan Law acted as legal advisors to Guangdong Hec Technologyholding Co., Ltd. Zou Jun, Chen Yi and Yang Ling of KPMG Huazhen Certified Public Accountants acted as accountants to Yichang Dongyangguang Pharmaceutical Co., Ltd. Hu Shaoxian, Li Yuanliang and Peng Zhuo of Pan-China Certified Public Accountants LLP acted as accountants to Guangdong Hec Technologyholding Co., Ltd.
Guangdong Hec Pharmaceutical Co., Ltd. and Hong Kong Hec Sales Co., Ltd completed the acquisition of 51.4% stake in Yichang Dongyangguang Pharmaceutical Co., Ltd. from Guangdong Hec Technologyholding Co., Ltd (SHSE:600673) on December 31, 2021.
Guangdong Hec Technology Holding Co Ltd is a China-based company mainly engaged in the production and sales of electronic components, aluminum foil, new chemical materials and energy materials. The electronic components business is mainly engaged in the research and development, production and sales of electrode foils for aluminum electrolytic capacitors, laminated foils, aluminum electrolytic capacitors and soft magnetic materials. The aluminum foil business is mainly engaged in the production of electronic optical foil, hydrophilic foil, brazing foil and battery aluminum foil. The new chemical materials business is mainly engaged in the production of chlor-alkali chemical products and new environmentally friendly refrigerants. The energy materials business is mainly engaged in the production of lithium iron phosphate and ternary materials. The Company mainly operates its businesses in the domestic and overseas markets.
Guangdong Hec Pharmaceutical Co., Ltd. and Hong Kong Hec Sales Co., Ltd completed the acquisition of 51.4% stake in Yichang Dongyangguang Pharmaceutical Co., Ltd. from Guangdong Hec Technologyholding Co., Ltd.
GUANGDONG HEC TECHNOLOGY HOLDING CO., LTD 
